南模生物11月11日获融资买入187.27万元，融资余额6773.21万元

Group 1 - The core viewpoint of the news is that Nanmo Bio experienced a slight decline in stock price and had notable financing activities on November 11, indicating a high level of financing balance relative to its market value [1] - On November 11, Nanmo Bio's financing buy amount was 1.87 million yuan, while the financing repayment was 2.23 million yuan, resulting in a net financing buy of -0.36 million yuan [1] - As of November 11, the total financing and securities lending balance for Nanmo Bio was 67.73 million yuan, which accounts for 1.95% of its circulating market value, indicating a high level compared to the past year [1] Group 2 - As of September 30, the number of shareholders for Nanmo Bio was 6,687, an increase of 2.53% from the previous period, while the average circulating shares per person decreased by 2.47% to 11,658 shares [2] - For the period from January to September 2025, Nanmo Bio achieved an operating income of 303 million yuan, representing a year-on-year growth of 14.29%, and a net profit attributable to the parent company of 26.76 million yuan, which is a significant increase of 276.14% year-on-year [2] Group 3 - Since its A-share listing, Nanmo Bio has distributed a total of 30.04 million yuan in dividends, with 10.00 million yuan distributed over the past three years [3] - As of September 30, 2025, Tianhong Medical Health A became the tenth largest circulating shareholder with 377,400 shares, marking its entry as a new shareholder, while Rongtong Health Industry Flexible Allocation Mixed A/B exited the top ten circulating shareholders [3]